Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06581198 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)

Name: A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN) — clinical trial record (NCT06581198)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusActive, Not Recruiting

PhasePhase 2

SponsorNovartis Pharmaceuticals

Started2024-09-04

View on ClinicalTrials.gov ↗

The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel (administered once following lymphodepletion) in patients with active, refractory systemic lupus erythematosus (SLE) or active, refractory lupus nephritis (LN).

Amendment history 3 changes detected by DataLookout

2026-09-03

Enrollment closed, study ongoing

2026-09-03

Trial sites expanded: 101 → 107 locations

2026-06-04

Trial sites expanded: 93 → 101 locations

Trial Details

NCT Number	NCT06581198
Lead Sponsor	Novartis Pharmaceuticals
Conditions	Lupus Erythematosus, Systemic, Lupus Nephritis
Enrollment	179 participants
Start Date	2024-09-04
Primary Completion	2028-02-14 (estimated)
Study Completion	2032-02-06 (estimated)
Updated on ClinicalTrials.gov	2026-09-02